Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Vishwajith Sridharan (15047154) (author)
Άλλοι συγγραφείς:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Έκδοση:	2025
Θέματα:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
ανά: Evan C. Chen (15054014)
Έκδοση: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
ανά: Jiachun Su (16990970)
Έκδοση: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
ανά: Joel R. Eisner (15132120)
Έκδοση: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
ανά: Joel R. Eisner (15132120)
Έκδοση: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
ανά: Joel R. Eisner (15132120)
Έκδοση: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
ανά: Nicholas T. Younger (14956251)
Έκδοση: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
ανά: Nicholas T. Younger (14956251)
Έκδοση: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
ανά: Nicholas T. Younger (14956251)
Έκδοση: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
ανά: Nicholas T. Younger (14956251)
Έκδοση: (2025)

Genetic variation and mRNA expression of the <i>ELOVL6</i> and <i>CRTC2</i> genes in Kalmyk cattle
ανά: Nurlybay Kazhgaliyev (9904228)
Έκδοση: (2025)

APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
ανά: Miao-Jin Ji (22676552)
Έκδοση: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
ανά: Natalie C. Fisher (15046025)
Έκδοση: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
ανά: Carlotta Antoniotti (15352506)
Έκδοση: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
ανά: Carlotta Antoniotti (15352506)
Έκδοση: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
ανά: Carlotta Antoniotti (15352506)
Έκδοση: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
ανά: Katie E. Hebron (15046889)
Έκδοση: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
ανά: Ruth Flümann (15123900)
Έκδοση: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
ανά: Chong Kin Liam (15331321)
Έκδοση: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
ανά: Chong Kin Liam (15331321)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_s94dle0v3h6tpddaocj83q3e0i